Indeed, the combination of TMZ and PARP inhibition against gliomas (sometimes including irradiation) is being or has been tested in clinical trials (NCT03212742; NCT03749187; NCT03914742; NCT01514201; NCT00994071; NCT02152982). The gene discussed is PARP1; the disease is glioma.